$ESPR на benzinga отчёт уже 25 минут как выложен, а earningswhispers ещё молчат, гм. Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(3.89) per share which missed the analyst consensus estimate of $(3.76) by 3.46 percent. This is a 72.12 percent decrease over losses of $(2.26) per share from the same period last year. The company reported quarterly sales of $9.64 million which missed the analyst consensus estimate of $12.52 million by 23.02 percent. This is a 881.47 percent increase over sales of $982.00 thousand the same period last year.